Skip to main content

Table 1 Baseline clinical characteristics and laboratory findings in RA patients with different response to anti-TNF-α therapy

From: Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy

  RA with anti-TNF-α Rx. Healthy control
  Moderate-good responders (n= 36) Non- responders (n= 12) (n= 12)
Mean age, years 50.4 ± 14.5 49.3 ± 10.8 47.6 ± 8.1
Female (%) 29 (80.6%) 10 (83.3%) 10 (83.3%)
Disease duration, years 5.44 ± 2.42 5.37 ± 2.37 NA
RF positivity (%) 30 (83.3%) 11 (91.6%) NA
Anti-CCP positivity (%) 29 (80.6%) 10 (83.3%) NA
ESR (mm/1st hr) 48.9 ± 25.4 63.8 ± 24.4 NA
DAS-28 7.18 ± 0.74 7.33 ± 0.94 NA
Daily steroid dose (mg) 6.5 ± 2.1 6.9 ± 2.4 NA
TNF-α inhibitors    
   Etanercept (n = 14) 10 (71.4%) 4 (28.6%) NA
   Adalimumab (n = 34) 26 (76.5%) 8 (23.5%) NA
Used DMARDs    
   Methotrexate 33 (91.7%) 11 (91.6%) NA
   Sulfasalazine 31 (86.1%) 10 (83.3%) NA
   Hydroxychloroqine 32 (88.9%) 10 (83.3%) NA
   Ciclosporine 14 (38.9%) 5 (41.7%) NA
  1. Data are presented as mean ± SD or number (percentage).
  2. RA, rheumatoid arthritis; Anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, disease activity score for 28-joints; DMARDs, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; NA, not applicable; RF, rheumatoid factor; TNF-α, tumor necrosis factor-α.